|57.49||+0.9900||+1.75%||Vol 90.37K||1Y Perf 71.42%|
|Oct 4th, 2023 16:00 DELAYED|
|- -||0.06 0.10%|
|Target Price||43.25||Analyst Rating||Strong Buy 1.00|
|Potential %||-24.77||Finscreener Ranking||★★★★ 52.98|
|Insiders Trans % 3/6/12 mo.||-/100/100||Value Ranking||★★+ 49.02|
|Insiders Value % 3/6/12 mo.||-/100/100||Growth Ranking||+ 31.62|
|Insiders Shares Cnt. % 3/6/12 mo.||-/100/100||Income Ranking||— -|
|Price Range Ratio 52W %||75.78||Earnings Rating||Strong Buy|
|Market Cap||1.17B||Earnings Date||8th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||8th Nov 2023|
|Estimated EPS Next Report||0.55|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||125.48K|
|Avg. Monthly Volume||153.74K|
|Avg. Quarterly Volume||147.86K|
ANI Pharmaceuticals Inc. (NASDAQ: ANIP) stock closed at 56.5 per share at the end of the most recent trading day (a -0.65% change compared to the prior day closing price) with a volume of 80.25K shares and market capitalization of 1.17B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 338 people. ANI Pharmaceuticals Inc. CEO is Nikhil Lalwani.
The one-year performance of ANI Pharmaceuticals Inc. stock is 71.42%, while year-to-date (YTD) performance is 42.9%. ANIP stock has a five-year performance of 4.55%. Its 52-week range is between 31.21 and 65.89, which gives ANIP stock a 52-week price range ratio of 75.78%
ANI Pharmaceuticals Inc. currently has a PE ratio of -9.50, a price-to-book (PB) ratio of 2.46, a price-to-sale (PS) ratio of 3.32, a price to cashflow ratio of 100.40, a PEG ratio of -, a ROA of -12.16%, a ROC of -10.06% and a ROE of -29.20%. The company’s profit margin is -19.65%, its EBITDA margin is -1.80%, and its revenue ttm is $222.15 Million , which makes it $12.73 revenue per share.
Of the last four earnings reports from ANI Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.55 for the next earnings report. ANI Pharmaceuticals Inc.’s next earnings report date is 08th Nov 2023.
The consensus rating of Wall Street analysts for ANI Pharmaceuticals Inc. is Strong Buy (1), with a target price of $43.25, which is -24.77% compared to the current price. The earnings rating for ANI Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ANI Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ANI Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 5.65, ATR14 : 1.77, CCI20 : -147.48, Chaikin Money Flow : -0.31, MACD : -0.83, Money Flow Index : 16.27, ROC : -9.44, RSI : 35.55, STOCH (14,3) : 9.86, STOCH RSI : 0.00, UO : 42.22, Williams %R : -90.14), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ANI Pharmaceuticals Inc. in the last 12-months were: Gassert Chad (Sold 20 000 shares of value $1 026 400 ), Shanmugam Muthusamy (Sold 23 469 shares of value $1 220 844 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.